INmune Bio (NASDAQ: INMB) Secures FDA Fast Track for Alzheimer’s Drug
Expert Analysis INmune Bio (NASDAQ: INMB) has reached a significant milestone by obtaining Fast Track designation from the FDA for its novel therapy XPro™ (pegipanermin), aimed at treating early Alzheimer’s disease. This strategic advancement highlights the company’s commitment to addressing neuroinflammation through selective soluble TNF inhibition, a promising approach in battling neurodegenerative conditions. The FDA’s recognition indicates strong potential for XPro™ to make notable clinical impacts, especially given the increasing…
